0000000000021333

AUTHOR

Jole Ventriglia

showing 2 related works from this author

Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus …

2016

e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseGemcitabineOncologyPancreatic cancerInternal medicineImmunologymedicineOverall survivalNeutrophil to lymphocyte ratiobusinesshuman activitieshealth care economics and organizationsNab-paclitaxelmedicine.drugJournal of Clinical Oncology
researchProduct

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine…

2018

Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according…

0301 basic medicinemedicine.medical_specialtyArticle Subjectmedicine.medical_treatmentGastroenterologyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineNeutrophil to lymphocyte ratiolcsh:RC799-869ChemotherapyHepatologyProportional hazards modelbusiness.industryGastroenterologymedicine.diseasePrimary tumorGemcitabine030104 developmental biology030220 oncology & carcinogenesisPropensity score matchinglcsh:Diseases of the digestive system. Gastroenterologybusinessmedicine.drugResearch ArticleGastroenterology Research and Practice
researchProduct